Hot Products

Basic Information

Post buying leads

Suppliers

Cas Database

Name	Ticlopidine	EINECS	259-498-5
CAS No.	55142-85-3	Density	1.273±0.06 g/cm3(Predicted)
PSA	31.48000	LogP	3.89770
Solubility	N/A	Melting Point	210-212 °C
Formula	C14H14 Cl N S	Boiling Point	117-120 °C(Press: 0.5 Torr)
Molecular Weight	263.791	Flash Point	N/A
Transport Information	N/A	Appearance	N/A
Safety		Risk Codes	R34
Molecular Structure		Hazard Symbols	C,Xi
Synonyms	PCR 5332;Ticlid; Ticlopidine; Tiklyd	Article Data	16

Ticlopidine Chemical Properties

Molecular structure of Ticlopidine (CAS NO.55142-85-3) is:

Product Name: Ticlopidine
CAS Registry Number: 55142-85-3
IUPAC Name: 5-[(2-Chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
Molecular Weight: 263.78566 [g/mol]
Molecular Formula: C₁₄H₁₄ClNS
XLogP3-AA: 3.6
H-Bond Donor: 0
H-Bond Acceptor: 1
EINECS: 259-498-5
Index of Refraction: 1.638
Molar Refractivity: 74.43 cm³
Molar Volume: 207 cm³
Surface Tension: 51.5 dyne/cm
Density: 1.273 g/cm³
Flash Point: 175.9 °C
Enthalpy of Vaporization: 61.38 kJ/mol
Boiling Point: 367.3 °C at 760 mmHg
Vapour Pressure: 1.38E-05 mmHg at 25 °C
Classification Code: Cardiovascular Agents ;Drug / Therapeutic Agent ;Fibrin Modulating Agents ;Fibrinolytic agents ;Hematologic Agents ;Human Data ;Platelet aggregation inhibitors
Canonical SMILES: C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
InChI: InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
InChIKey: PHWBOXQYWZNQIN-UHFFFAOYSA-N

Ticlopidine Uses

Ticlopidine (CAS NO.55142-85-3) can be used in these actions:
1、Inihibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents platelet expression of glycoprotein IIb/IIIa which prevents platelet binding to fibrinogen.
2、Prolongs bleeding time.
3、Decreased incidence of stroke in high-risk patients.

Ticlopidine Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	LDLo	oral	336mg/kg/47D- (336mg/kg)	LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BLOOD: AGRANULOCYTOSIS BLOOD: THROMBOCYTOPENIA	Annals of Pharmacotherpy. Vol. 28, Pg. 1236, 1994.
man	TDLo	oral	350mg/kg/7W-I (350mg/kg)	BLOOD: AGRANULOCYTOSIS	Postgraduate Medical Journal. Vol. 74, Pg. 126, 1998.
man	TDLo	oral	429mg/kg/6OD- (429mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Lancet. Vol. 1, Pg. 407, 1984.
monkey	LD50	intraperitoneal	500mg/kg (500mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
monkey	LD50	oral	> 6gm/kg (6000mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
mouse	LD50	intraperitoneal	1250mg/kg (1250mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
mouse	LD50	intravenous	88mg/kg (88mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
mouse	LD50	oral	600mg/kg (600mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
rat	LD50	intraperitoneal	> 5gm/kg (5000mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
rat	LD50	intravenous	70mg/kg (70mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SKIN AND APPENDAGES (SKIN): HAIR: OTHER LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
rat	LD50	oral	1780mg/kg (1780mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: PLEURAL THICKENING SKIN AND APPENDAGES (SKIN): HAIR: OTHER	New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
women	TDLo	oral	100mg/kg/10D- (100mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED BLOOD: EOSINOPHILIA	American Journal of Kidney Diseases. Vol. 25, Pg. 934, 1995.
women	TDLo	oral	350mg/kg/5W-I (350mg/kg)	LIVER: LIVER FUNCTION TESTS IMPAIRED	Annals of Pharmacotherpy. Vol. 33, Pg. 939, 1999.
women	TDLo	oral	600mg/kg/60D- (600mg/kg)	BLOOD: APLASTIC ANEMIA BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Israel Journal of Medical Sciences. Vol. 31, Pg. 444, 1995.

Ticlopidine Specification

Ticlopidine , its cas register number is 55142-85-3. It also can be called Ticlopidine [INN:BAN] ; 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine ; Ticlopidina ; Ticlopidinum ; Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-((2-chlorophenyl)methyl)- ; Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro- .It is an antiplatelet drug in the thienopyridine family. Also it is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 55142-85-3